Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 , a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
TP-03 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
CoTec Holdings Corp. Announces Partial Settlement and Amendment and Restatement of Convertible Loan Facilities
Westport to Showcase High?Pressure CNG Fuel System for North American Heavy?Duty Fleets at ACT Expo 2026
